Stockholder Alert: Robbins LLP Informs MoonLake Immunotherapeutics Stockholders that a Class Action Lawsuit was Filed Against the Company

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company misled investors regarding the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][2]. Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information about the differences between its Nanobody drug SLK and traditional monoclonal antibodies, including: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [2]. - SLK's Nanobody structure does not provide a clinical benefit over BIMZELX's monoclonal structure [2]. - The supposed increased tissue penetration of SLK does not translate to improved clinical efficacy [2]. - Consequently, the positive statements made by the company regarding SLK's superiority lacked a reasonable basis [2]. Stock Price Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3]. Next Steps for Investors - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff, representing other class members in the litigation [4]. - Investors can remain absent class members and still be eligible for recovery without taking any action [4]. Company Background - Robbins LLP, the firm leading the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].